GTBP News and Press, GT Biopharma Inc. From 04/11/22

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo - Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor microenvironment BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (&...

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update PR Newswire Presented novel TriKE ® pre-clinical data driving NK cell immunotherapy against non-small cell lung cancer (NSCLC) in the hypoxic solid tumor mic...

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting PR Newswire - GTB-5550 TriKE significantly enhances NK cell mediated killing of myeloma cells, even in the relatively low B7-H3...

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 - Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and prov...

GT Biopharma (NASDAQ: GTBP) is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE(R) NK cell engager platform. The company’s TriKE(R) platform is designed to harness and e...

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 PR Newswire BRISBANE, Calif. , March 3, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing inn...

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences PR Newswire BRISBANE, Calif. , Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based ...

GT Biopharma (NASDAQ:GTBP), a clinical-stage immunooncology company, has named Manu Ohri as its Chief Financial Officer (CFO) with immediate effect. Ohri has over 25 years of management, finance and public accounting experience and has served as CFO for multiple public companies. He was previ...

GT Biopharma Appoints Manu Ohri as Chief Financial Officer PR Newswire BRISBANE, Calif. , Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Com...

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference PR Newswire BRISBANE, Calif. , Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics base...